Bridging Strategies to Allogeneic Transplant for Older AML Patients

Cancers - Switzerland
doi 10.3390/cancers10070232
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Age Does Not Adversely Influence Outcomes Among Patients Older Than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for AML and Myelodysplastic Syndrome

Bone Marrow Transplantation
TransplantationHematology
2017English

Impact of Pre-Transplant Measurable Residual Disease on Relapse Incidence and Progression-Free Survival in Older AML/MDS Patients Following Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Bendamustine-Brentuximab: Bridging to Transplant

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Bridging Strategies and Their Association With Post Heart Transplant Outcomes

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

SGN-CD33A: Case Reports of Anti-Leukemic Activity and Bridge to Allogeneic Stem Cell Transplant (SCT) in Patients With Acute Myeloid Leukemia (AML)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Pre-Transplant MRD Predicts Outcome Following Reduced-Intensity and Myeloablative Allogeneic Hemopoietic SCT in AML

Bone Marrow Transplantation
TransplantationHematology
2014English

Outcomes After Allogeneic Transplant in Patients With Wiskott-Aldrich Syndrome.

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Donor Lymphocyte Experience in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Modern Strategies in AML Treatment

Russian Journal of Children Hematology and Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy